Opthea Limited, a prominent clinical stage biopharmaceutical company from Australia, has recently gained attention for its revolutionary therapies primarily designed to combat eye diseases. The company relies on a robust intellectual property portfolio, with a focus on Vascular Endothelial Growth Factors (VEGF) including VEGF-C, VEGF-D, and VEGF Receptor-3, to develop cutting-edge treatments for diseases related to blood and lymphatic vessel growth and vascular leakage. Opthea's flagship product, OPT 302, is a soluble form of VEGFR 3 that is currently undergoing clinical trials as a highly innovative therapy for wet neovascular age-related macular degeneration and diabetic macular edema (DME). In addition, Opthea aims to leverage its impressive VEGF-C/D inhibitors to supplement VEGF-A inhibitors for the treatment of various retinal diseases, including wet neovascular AMD. Founded in 1984 and formerly known as Circadian Technologies Limited, Opthea Limited has established itself as a pioneering force in the healthcare industry, advancing fine-tuned techniques to treat debilitating eye conditions. The company's headquarters are located in South Yarra, Australia.
Optiva's ticker is OPT
The company's shares trade on the ASX stock exchange
They are based in South Yarra, Australia
There are 11-50 employees working at Optiva
It is optiva.com
Optiva is in the Healthcare sector
Optiva is in the Biotechnology industry
The following five companies are Optiva's industry peers: